KensaGroup creates, launches and develops leading edge intellectual property platforms into successful technology-based businesses. KensaGroup uses a proprietary approach to identify and evaluate promising discoveries from universities and corporate research initiatives, then creates the necessary scientific, institutional, and financial bridges that lead from initial discovery to successful commercialization.
08.03.20 - Applying AI to the emerging field of personalized medicine...more
07.17.20 - Novomer to Probe Functional Beta-Lactones to Enhance Virus Deactivation...more
05.28.20 - Multiple Myeloma DREAM Challenge Reveals Epigenetic Regulator PHF19 as Marker of Aggressive Disease...more
01.07.20 - GNS Healthcare announces strategic investment from Merck Global Health Investment Fund...more
11.25.19 - FDA selects NovaSterilis, Steris, Stryker and Noxilizer for challenge grant to offer alternative to ethylene oxide...more
KensaGroup, LLC
2415 N. Triphammer Road
Ithaca, NY 14850
phone: 1.607.330.2307
Fax: 1.607.257.1139